A novel hydrogel scaffold for the prevention or reduction of the recurrence of keloid scars postsurgical excision - 23/10/13
Doi : 10.1016/j.jaad.2013.06.025
Brian Berman, MD, PhD a, b, ⁎ 
, Srikanth Garikaparthi, MD, MS, MCH, DNB, FRCSEd c, Eugene Smith, MD c, Jessica Newburger, DO b
, Srikanth Garikaparthi, MD, MS, MCH, DNB, FRCSEd c, Eugene Smith, MD c, Jessica Newburger, DO b a Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Florida
b Center for Clinical and Cosmetic Research, Aventura, Florida
c Princess Margaret Hospital, University of West Indies School of Clinical Medicine and Research, Nassau, Bahamas
∗Correspondence to: Brian Berman, MD, PhD, Center for Clinical and Cosmetic Research, 2925 Aventura Blvd, Suite 205, Aventura, FL 33180
| Supported by Halscion Inc, Suwanee, Georgia. |
|
| Disclosure: Dr Berman has served as a consultant for GSK, Excaliard, Pfizer, and Halscion; an adviser for Pfizer and Halscion; and an investigator for Halscion. Dr Garikaparthi has served as an investigator for Halscion. Drs Smith and Newburger have no conflicts of interest to declare. |
|
| Preliminary data were presented at the American Academy of Dermatology Annual Meeting in San Diego, California, on March 16, 2012. |
© 2013
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 69 - N° 5
P. 828-830 - novembre 2013 Retour au numéro
Article précédent
- Large lymphatic vessel density in primary malignant melanoma predicts sentinel node status
- Ferdinand Toberer, Siegfried Werchau, Efstathia Christia, Alexander Enk, Peter Schirmacher, Peter Helmbold
- Lichen planopilaris treated by the peroxisome proliferator activated receptor-? agonist pioglitazone: Lack of lasting improvement or cure in the majority of patients
- Philipp Spring, Zoi Spanou, Pierre A. de Viragh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?